Charles Schwab Investment Management Inc. Boosts Holdings in Astera Labs, Inc. (NASDAQ:ALAB)

Charles Schwab Investment Management Inc. grew its holdings in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 12.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 132,472 shares of the company's stock after buying an additional 15,008 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.08% of Astera Labs worth $17,546,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Steward Partners Investment Advisory LLC lifted its holdings in shares of Astera Labs by 99.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 199 shares of the company's stock worth $26,000 after buying an additional 99 shares during the period. Kestra Investment Management LLC bought a new position in Astera Labs during the 4th quarter worth about $28,000. GAMMA Investing LLC increased its position in Astera Labs by 78.3% during the 4th quarter. GAMMA Investing LLC now owns 510 shares of the company's stock valued at $68,000 after purchasing an additional 224 shares during the period. CIBC Asset Management Inc raised its holdings in shares of Astera Labs by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 4,757 shares of the company's stock valued at $630,000 after purchasing an additional 237 shares in the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Astera Labs in the 4th quarter worth approximately $36,000. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

Astera Labs Stock Up 3.8 %

Shares of Astera Labs stock traded up $2.68 on Monday, reaching $73.78. 2,412,568 shares of the stock were exchanged, compared to its average volume of 3,695,158. Astera Labs, Inc. has a twelve month low of $36.22 and a twelve month high of $147.39. The firm has a market capitalization of $11.96 billion and a price-to-earnings ratio of -42.65. The business has a 50 day moving average price of $91.24 and a two-hundred day moving average price of $89.57.

Remove Ads

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.26 by ($0.16). Astera Labs had a negative return on equity of 10.40% and a negative net margin of 21.05%. Research analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current year.

Wall Street Analysts Forecast Growth

ALAB has been the topic of several recent research reports. Craig Hallum increased their target price on Astera Labs from $105.00 to $125.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and issued a $140.00 target price on shares of Astera Labs in a research note on Tuesday, February 11th. Raymond James started coverage on shares of Astera Labs in a research report on Friday, March 14th. They set an "outperform" rating and a $82.00 price target for the company. Stifel Nicolaus lifted their price objective on shares of Astera Labs from $100.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, January 6th. Finally, Morgan Stanley decreased their target price on shares of Astera Labs from $142.00 to $114.00 and set an "equal weight" rating for the company in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Astera Labs presently has a consensus rating of "Buy" and an average price target of $112.77.

Insider Buying and Selling

In related news, General Counsel Philip Mazzara sold 50,000 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $87.46, for a total value of $4,373,000.00. Following the completion of the transaction, the general counsel now owns 191,209 shares of the company's stock, valued at approximately $16,723,139.14. This represents a 20.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Truett Tate sold 125,800 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $82.53, for a total value of $10,382,274.00. Following the transaction, the chief financial officer now owns 244,242 shares in the company, valued at $20,157,292.26. This represents a 34.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 570,990 shares of company stock valued at $50,242,702 over the last ninety days.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.